Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
October 20, 2026 · 7:58 PM · PHILADELPHIA
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg)...
- PublishedOctober 20, 2026 · 7:58 PM
- LocationPHILADELPHIA
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →